While the majority of the adults infected with hepatitis C virus are baby boomers-people between the ages of 51 and 71 years-Alaska is seeing a large spike in infection rates among young adults.
While the majority of the adults infected with hepatitis C virus (HCV) are baby boomers—people between the ages of 51 and 71 years—Alaska is seeing a large spike in infection rates among young adults.
A bulletin published by the State of Alaska Section of Epidemiology reported that there have been large increases of HCV infection rates among 18- to 29-year-olds. The largest reported change was an increase of 490% from 2011 to 2015 in southeastern Alaska. The gulf coast region of Alaska had the smallest change, but still reported an increase of 45%.
According to the bulletin, injection drug use (IDU) among young adults is likely the cause of the rising number of HCV-infected individuals between the ages of 18 and 29.
“Previous Alaska data on HCV prevalence demonstrated the majority of HCV cases reported were among ‘baby boomers,’” the authors of the report wrote. “The recent increase in HCV among young adults follows national HCV trends and we presume that our HCV-infected young adults share similar IDU risk factors.”
Although the number of reported HCV cases rose considerably across all age groups from 2011 to 2015 in Alaska, the increase was proportionally highest among young adults. In 2011, young adults represented 22% of all newly reported HCV cases, but in 2015, they represented 31% of new cases.
In addition, the Section of Epidemiology found that while most cases of new HCV infection across all age groups were in males, among young adults, females represented the most cases of new HCV infection.
The report noted that one of the ways to decrease IDU, and HCV infection, is through the use of syringe exchange programs.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More